Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.

Constipation impedes desmopressin treatment success in nocturnal enuresis

13 Jun 2019

Response to desmopressin treatment for nocturnal enuresis (NE) in children appears to be compromised in the presence of constipation, particularly in children with severe enuresis and those prescribed low doses, as reported in a recent study.

The study included 383 paediatric patients (52.7 percent boys) aged 5–15 years, among whom 126 (32.9 percent) had primary NE and 257 (67.1 percent) had secondary NE. About a third of the population had a family history of NE (32.6 percent), and 14 percent of patients presented with constipation.

Severe enuresis was more common among patients with constipation than among nonconstipated controls (94.4 percent vs 72.9 percent; p=0.001). NE severity was significantly correlated to responses to desmopressin treatment (p=0.026).

Patients with constipation had significantly lower complete response rate relative to those without constipation. Of note, there was a significant association seen between constipation and the effectiveness of desmopressin both among monosymptomatic NE or nonmonosymptomatic patients with NE.

Complete response rate was also significantly lower in constipated vs nonconstipated patients in the subgroup of those who received 0.2 mg of desmopressin. On the other hand, constipation showed no significant association with treatment response in subgroups of patients with mild-to-moderate NE and 0.4-mg desmopressin.

More studies on subclassification of enuretic patients with a large sample size are warranted to verify the association between constipation and the effectiveness of desmopressin, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.